{"DataElement":{"publicId":"4619915","version":"1","preferredName":"Patient Antibody Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the antibody therapy criteria in order to participate in a clinical trial.","longName":"XBOD_TX_CTEC_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3534679","version":"1","preferredName":"Patient Antibody Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"Information related to patient receiving treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells, as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2233604v1.0:3534677v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3534677","version":"1","preferredName":"Antibody Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"Treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C15542:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibody Therapy","conceptCode":"C15542","definition":"Treatment with injections of antibodies to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2BD9-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"ONEDATA","dateModified":"2012-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2BEA-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEL","dateCreated":"2012-07-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways?","url":null,"context":"Theradex"},{"name":"Has received prior therapy wi","type":"Preferred Question Text","description":"Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, ziv-aflibercept or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient received treatment with any therapy on the PD-1/PD-L1 axis or anti-CTLA-4 inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Patient has not received prior treatment with anti-PD-1 or anti-PD-L1?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have disease that is documented to be refractory to at least one PD1/PD-L1 inhibitor, defined as disease progression following at least 2 infusions of the same drug?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient received prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has bisphosphonate, or RANKL antibody therapy been initiated or the dose/regimen adjusted within 30 days prior to Cycle 1 Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or pathway-targeting agents?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have a history of prior treatment with anti-CTLA-4 antibody, anti-PD 1 antibody or anti-PDL1 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient has had prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents are following requirements  met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Patient has not received prior anti-PD-1 or ant-PD-L1 therapy after ACT and before study atezolizumab (MPDL3280A) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient received treatment with any therapy on the PD-1/PD-L1 axis or anti-CTLA-4 inhibitors, unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohort?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient received prior treatment with any anti-PD-1 blocking therapies or HDACi, or anti-CTLA-4 antibody, CD137 agonist or other immune activating therapy such as anti-CD 40 antibody within the last 3 months of enrollment in the study?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or ziv-aflibercept?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD1 or anti-CTLA4 therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient has had prior treatment with anti-CTLA-4 are the following requirements met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD-1 or anti-PD-L1 or pathway-targeting agents?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient has prior exposure to immune mediated therapy including anti-CTLA-4 agent, but excluding therapeutic anticancer vaccines and anti-PD-1 or anti-PD-L1 therapy in NSCLC patients?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient had prior exposure to immune mediated therapy including anti-CTLA-4 agent, but excluding therapeutic anticancer vaccines and anti-PD-1 or anti-PD-L1 therapy in NSCLC patients?","url":null,"context":"Theradex"},{"name":"theradex - 22","type":"Alternate Question Text","description":"Is patient greater than or equal to 15 weeks since prior anti-CD137 or anti-CTLA-4 (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Has patient received treatment with any anti-PD-1 or anti-PD-L1 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has the patient received checkpoint inhibitors such as anti-CTLA-4 or anti-PD1/PD-L1 and for nitrosoureas or mitomycin C within 6 weeks prior to C1D1?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD-1, or anti-PD-L1, therapeutic antibody or pathway-targeting agents or eribulin?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If patient is registered to Dose Escalation or Dose Expansion Part 1, has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or ziv-aflibercept?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient has received prior anti-CTLA-4 have a minimum of 12 weeks elapsed from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose, and there is no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has patient received treatment with any anti-PD-1 or anti-PD-L1 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD-1 or anti-PD-L1 therapeutic antibody or pathway-targeting agents?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient had prior exposure to immune-mediated therapy, including durvalumab and tremelimumab, except for NSCLC patients who are allowed anti-PD-1 or anti_PD-L1 therapy (including durvalumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Has patient had prior exposure to immune mediated therapy, including durvalumab and tremelimumab, except for anti-PD-1 or anti-PD-L1 therapy (including durvalumab) in NSCLC patients?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Has patient received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Has patient received anticancer antibodies within 4 weeks or radio or toxin immunoconjugates within 2 weeks prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Patient has not received prior anti-PD-1 or ant-PD-L1 therapy after ACT and before study atezolizumab (MPDL3280A) administration?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Has patient received prior treatment with a Pi3 kinase inhibitor, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Has patient received prior treatment with P13K/AKT/mTOR inhibitor and a checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) in combination?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Has patient had prior exposure to immune-mediated therapy, including durvalumab and tremelimumab, except for NSCLC/SCCHN/Bladder Cancer/cSCC patients who are allowed anti-PD-1 or anti_PD-L1 therapy (including durvalumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Has patient received prior therapy with any anti-PD-1 or anti-PD-L1?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathway, for their current cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Has patient received prior PD-L1/PD-1/PD-L2 or EZH2 inhibitor therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"If patient has received prior anti-PD-1, anti-PD-L1 or anti-CTLA-4 has patient experienced: a toxicity that led to permanent discontinuation of prior immunotherapy, a  greater than or equal to grade 3 immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy, or has required the use of additional immunosuppression other than corticosteroids for the management of an AE, has experienced recurrence of an AE if re-challenged, and currently require maintenance doses of more than 10 mg prednisone or equivalent per day?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Has patient received prior treatment with PD-1, PD-L1 or PD-L2 inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Has patient received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Has patient received Anti-PD-1, anti-PD-L1, or anti-PD-L2, for a prior, unrelated, curatively-treated malignancy, within last 3 months of enrollment in the study?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Has patient received any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736 (durvalumab) or tremelimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Has patient received prior treatment with eribulin?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"If patient is in the Doublet cohort and Triplet safety run-in phase, has patient received treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting immune checkpoint pathways?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Have at least 21 days elapsed since infusion of the last dose of antibody?","url":null,"context":"COG"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Has patient received treatment with a combination of anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"If patient has received prior treatment with anti-CTLA-4, was minimum of 12 weeks from the first dose of anti-CTLA-4 and greater than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"If patient is in the expansion phase, has patient received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"If patient is enrolled to the atezolizumab monotherapy arm and has had prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents, are the following requirements and all other selection criteria met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-CTLA-4, anti-PD-1, or anti-PD-L1or other immune checkpoint inhibitor therapeutic antibodies or pathway-targeting agents?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"If patient is in the dose escalation cohort and has received prior anti-PD-1/PD-L1 in MSI-H tumors, no grade 2 or more toxicities developed during that therapy requiring stopping immune checkpoint inhibition?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Has patient received prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-1, anti-PD-1, or anti-PD-L1 therapeutic antibodies, If enrolled in the randomized arms?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"If patient has received prior antibody drug, was the drug conjugate such as sacituzumab govitecan?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Has patient received any of the following prior therapies: Prior FGFR inhibitors or PD-1/PD-L1 immune check point inhibitors for MIBC and/or  prior platinum chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Has patient received prior therapy with EGFR inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient had prior treatment, for their current cancer, with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-LAG-3 or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways within 1 year of study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"If patient is registered to the Phase 1 portion of study, has patient received prior anti-CTLA-4, anti-PD-1, anti-PD-L1 or other immune checkpoint inhibitor therapeutic antibodies or pathway-targeting agents?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-6730-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"SOKKERL","dateModified":"2023-07-18","changeDescription":"12/5/16 tt, added CSI. 9676_Theradex_12.04.14_ghd","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"}}